Brexit Vote Dismays UK Pharma, Triggers Calls To Leverage NHS As Offset
The UK now urgently needs to leverage the uniqueness of its National Health System to attract global pharma companies and offset the anti-business message contained in Thursday's Brexit vote, and the government's imminent accelerated access review needs to contain the first elements of that objective, according to the Association of the British Pharmaceutical Industry.
You may also be interested in...
Roche's decision to return to the UK industry body the ABPI reflects the Swiss company’s considerable commercial interests in Britain and the need for drug makers operating there to work more closely together as the Brexit process begins.
The UK's Early Access to Medicines Scheme (EAMS) has been operational for two years, along with a "promising innovative medicine" (PIM) designation, to give patients timely access to new drugs for serious diseases before they are approved. The system has now been independently reviewed and Scrip talks to those in the industry that have first-hand experience of the process.
Less than two years after the first-ever cap on UK National Health Service drug prices was agreed, the country's Department of Health has announced it wants to change a central part of the pact on grounds it does not provide the NHS with adequate savings or price transparency.